[1. D. C. Baumgart, Treatment of inflammatory bowel disease: A review of medical therapy, World J. Gastroenterol. 21 (2008) 354-377; DOI: 10.3748/wjg.14.354.10.3748/wjg.14.354]Search in Google Scholar
[2. U. Klotz and M. Schwab, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 267-279; DOI: 10.1016/j.addr.2006.09.011.10.1016/j.addr.2006.09.011]Search in Google Scholar
[3. M. Jiménez and A. S. Peña, Budesonide for ulcerative colitis, Rev. Esp. Enferm. Dig. 98 (2006) 362-373; DOI: 1130-0108/2006/98/5/362-373.]Search in Google Scholar
[4. K. Dilger, M. Alberer, A. Busch, A. Enninger, R. Behrens, S. Koletzko, M. Stern, C. Beckmann and C. H. Gleiter, Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn’s disease, Aliment. Pharmacol. Ther. 23 (2006) 387-395; DOI: 10.1111/j.1365-2036.2006. 02771.x.]Search in Google Scholar
[5. J. Seidegård, L. Nyberg and O. Borgå, Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole, Eur. J. Pharm. Sci. 15 (2008) 264-70; DOI: 10.1016/j.ejps.2008.07.005.10.1016/j.ejps.2008.07.005]Search in Google Scholar
[6. L. F. Asghar and S. Chandran, Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J. Pharm. Pharm. Sci. 9 (2006) 327-338.]Search in Google Scholar
[7. Y. Krishnamachari, P. Madan and S. Lin, Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon, Int. J. Pharm. 29 (2007) 238-47; DOI: 10.1016/j.ijpharm.2007.02.015.10.1016/j.ijpharm.2007.02.015]Search in Google Scholar
[8. A. Makhlof, Y. Tozuka and H. Takeuchi, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm. 72 (2009) 1-8; DOI: 10.1016/j.ejpb.2008.12.013.10.1016/j.ejpb.2008.12.013]Search in Google Scholar
[9. United States Pharmacopoeia 32, National Formulary 29, USP Convention, Rockville 2002.]Search in Google Scholar
[10. J. Varshosaz, J. Emami, N. Tavakoli, A. Fassihi, M. Minaiyan, F. Ahmadi and F. Dorkoosh, Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis, Int. J. Pharm. 365 (2009) 69-76; DOI: 10.1016/j.ijpharm.2008.08.034.10.1016/j.ijpharm.2008.08.034]Search in Google Scholar
[11. J. Ding, X. Wang, T. Zhang, Q. Li and M. Luo, Optimization of RP-HPLC analysis of low molecular weight organic acids in soil, J. Liq. Chrom. Rel. Tech. 29 (2006) 99-111; DOI: 10.1080/10826070500363050.10.1080/10826070500363050]Search in Google Scholar
[12. T. Higuchi, Mechanism of sustained-action medication, J. Pharm. Sci. 52 (1963) 1145-1149; DOI: 10.1002/jps. 2600521210.]Search in Google Scholar
[13. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm. 15 (1983) 25-35; DOI: 10.1016/0378-5173(83)90064-9.10.1016/0378-5173(83)90064-9]Search in Google Scholar
[14. N. A. Peppas, Analysis of Fickian and non-Fickian drug release from polymers, Pharm. Acta Helv. 60 (1985) 110-111.]Search in Google Scholar
[15. P. Costa and J. M. Sonsa Lobo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133; DOI: 10.1016/S0928-0987(01)00095-1.10.1016/S0928-0987(01)00095-1]Search in Google Scholar
[16. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk and J. L. Wallace, Hapten-induced model of colonic inflammation and ulceration in the rat colon, Gastroenterology 96 (1989) 795-803.10.1016/0016-5085(89)90904-9]Search in Google Scholar
[17. S. Choudhary, A. Keshavarzian, S. Yong, M. Wade, S. Bocckino, B. J. Day and A. Banan, Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats, Dig. Dis. Sci. 46 (2001) 2222-2230; DOI: 10.1023/A: 1011975218006.]Search in Google Scholar
[18. S. Y. Zhou, Q. B. Mei, L. Liu, X. Guo, B. S. Qiu, D. H. Zhao and C. H. Cho, Delivery of glucocorticoid conjugates in rat gastrointestinal tract and its treatment for ulcerative colitis, Acta Pharmacol. Sin. 22 (2001) 761-764.]Search in Google Scholar
[19. J. L. Wallace and C. M. Keenan, An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis, Am. J. Physiol. 258 (1990) 527-534.]Search in Google Scholar
[20. C. B. Appleyard and J. L. Wallace, Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs, Am. J. Physiol. 269 (1995) 119-125.]Search in Google Scholar